Indivior Pharmaceuticals, Inc. INDV Business Segments — SG&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Indivior Pharmaceuticals, Inc. 's business segments — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Indivior Pharmaceuticals, Inc. 's business segments — SG&A?
- Indivior Pharmaceuticals, Inc. (INDV) reported business segments — SG&A of $124M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc. 's business segments — SG&A changed year-over-year?
- Indivior Pharmaceuticals, Inc. 's business segments — SG&A decreased by 6.8% year-over-year, from $133M to $124M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc. 's business segments — SG&A?
- Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc. 's business segments — SG&A has grown at a 10.6% compound annual growth rate (CAGR), from $469M to $635M.
- What does business segments — SG&A mean?
- Captures the combined costs of marketing, sales force operations, and general corporate overhead allocated to the segment. This metric highlights the level of investment required to support commercialization and administrative infrastructure.